ReviewMedical oncology (Northwood, London, England)2025
The role of E3 ligases and deubiquitinases in PD-L1 regulation and the tumor microenvironment in renal cell carcinoma.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research advances in epigenetic modifications and post-translational modifications in endothelial-mesenchymal transition.Epigenetics & chromatin · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is a complex and highly heterogeneous malignancy marked by an immunosuppressive tumor microenvironment, which facilitates immune evasion and disease progression. Programmed death-ligand 1 (PD-L1), a key immune checkpoint molecule expressed on tumor and immune cells, whose activation allows tumors to evade immune surveillance, plays a central role in modulating antitumor immunity in RCC. While the transcriptional and cytokine-mediated regulation of PD-L1 is well documented, emerging evidence emphasizes the critical influence of post-translational modifications particularly ubiquitination and deubiquitination in controlling PD-L1 stability and function. This review provides a comprehensive analysis of the ubiquitin-proteasome system (UPS), highlighting the roles of specific E3 ubiquitin ligases and deubiquitinases (DUBs) in modulating PD-L1 expression and their broader implications in RCC tumor biology. We further discuss how these proteins influence immune cell infiltration, tumor progression, and response to immunotherapy. The therapeutic potential of targeting UPS components, including proteasome inhibitors and proteolysis-targeting chimeras, is also explored. Understanding the UPS-mediated regulation of PD-L1 offers promising avenues for enhancing immunotherapeutic efficacy in RCC.
Indexed as
Identifiers
40728589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.